ReviewSeminars in immunopathology2012
Targeting the host-pathogen interface for treatment of Staphylococcus aureus infection.
Review in Seminars in immunopathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Piezoelectric Nanocoatings on Bio-Interfaces: Microenvironment Remodeling, Biofilm Disruption, and Immunomodulatory Integration.Microorganisms · 2026Review
- Harnessing Piezoelectric Biomaterials for Pathogenic Eradication and Tissue Regeneration.Exploration (Beijing, China) · 2026Review
- Piezoelectric Biomaterial with Advanced Design for Tissue Infection Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Barriers to and Facilitators of Hepatitis B Vaccination among the Adult Population in Indonesia: A Mixed Methods Study.Vaccines · 2023Article
- Cyanidin chloride protects mice from methicillin-resistantVirulence · 2022Article
- In Vitro Antibacterial Experiments of Qixingjian Decoction and Its Synergistic Interaction with Oxacillin against Clinical Isolates of Methicillin-ResistantEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Cajanin Stilbene Acid Inhibited Vancomycin-ResistantFrontiers in pharmacology · 2020Article
- Article
- ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation.Antimicrobial agents and chemotherapy · 2015Article
- Article
- Liposomal resiquimod for the treatment of Leishmania donovani infection.The Journal of antimicrobial chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recent emergence of methicillin-resistant Staphylococcus aureus both within and outside healthcare settings has accelerated the use of once reserved last line antibiotics such as vancomycin. With increased use of antibiotics, there has been a rapid rise in the rate of resistance development to the anti-MRSA drugs. As the antibiotic pipeline becomes strained, alternative strategies are being sought for future treatment of S. aureus. Here, we review several novel anti-staphylococcal strategies that, unlike conventional antibiotics, do not target essential gene products elaborated by the pathogen. The approaches seek instead to weaken the S. aureus defense by neutralizing its virulence factors or boosting host immunity. Other strategies target commensal bacteria that naturally colonize the human host to inhibit S. aureus colonization. Ultimately, the aim is to shift the balance between host defense and pathogen virulence in favor of inhibition of S. aureus pathogenic activities.
Indexed as
Identifiers
22089960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.